164 related articles for article (PubMed ID: 12673372)
21. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD.
Kay M; Wyllie R
Am J Gastroenterol; 2003 Apr; 98(4):717-20. PubMed ID: 12738445
[No Abstract] [Full Text] [Related]
22. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
Loftus EV
Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960
[No Abstract] [Full Text] [Related]
23. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
[TBL] [Abstract][Full Text] [Related]
24. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
Persoons P; Vermeire S; Demyttenaere K; Fischler B; Vandenberghe J; Van Oudenhove L; Pierik M; Hlavaty T; Van Assche G; Noman M; Rutgeerts P
Aliment Pharmacol Ther; 2005 Jul; 22(2):101-10. PubMed ID: 16011668
[TBL] [Abstract][Full Text] [Related]
25. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Lichtenstein GR
Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
[No Abstract] [Full Text] [Related]
26. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
Franchimont N; Putzeys V; Collette J; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Franchimont D; Fiasse R; Pelckmans P; Malaise M; Belaiche J; Louis E
Aliment Pharmacol Ther; 2004 Sep; 20(6):607-14. PubMed ID: 15352908
[TBL] [Abstract][Full Text] [Related]
27. Infliximab therapy in Crohn's disease: a pragmatic approach?
Kevans D; Keegan D; Mulcahy HE; O'Donoghue DP
Aliment Pharmacol Ther; 2006 Jul; 24(2):351-9. PubMed ID: 16842462
[TBL] [Abstract][Full Text] [Related]
28. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
29. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T
Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
[TBL] [Abstract][Full Text] [Related]
31. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab.
Carpenter E; Jackson MA; Friesen CA; Scarbrough M; Roberts CC
J Pediatr; 2004 Apr; 144(4):541-4. PubMed ID: 15069408
[TBL] [Abstract][Full Text] [Related]
32. Local injection of Infliximab for the treatment of perianal Crohn's disease.
Poggioli G; Laureti S; Pierangeli F; Rizzello F; Ugolini F; Gionchetti P; Campieri M
Dis Colon Rectum; 2005 Apr; 48(4):768-74. PubMed ID: 15768185
[TBL] [Abstract][Full Text] [Related]
33. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
34. [Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis].
Minnee RC; Stokkers P; Riemens SC; Hommes DW
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2290-5. PubMed ID: 16240855
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
36. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
[TBL] [Abstract][Full Text] [Related]
37. Severe lower gastrointestinal bleeding in Crohn's disease: successful control with infliximab.
Belaiche J; Louis E
Am J Gastroenterol; 2002 Dec; 97(12):3210-1. PubMed ID: 12492221
[No Abstract] [Full Text] [Related]
38. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients.
Di Sabatino A; Ciccocioppo R; Benazzato L; Sturniolo GC; Corazza GR
Aliment Pharmacol Ther; 2004 May; 19(9):1019-24. PubMed ID: 15113369
[TBL] [Abstract][Full Text] [Related]
39. Perianal Crohn's disease (Br J Surg 2004; 91: 801-814).
Olaison G; Almer S; Anderson P
Br J Surg; 2004 Oct; 91(10):1381. PubMed ID: 15382098
[No Abstract] [Full Text] [Related]
40. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
